Literature DB >> 1325539

Radiosurgery as part of the initial management of patients with malignant gliomas.

J S Loeffler1, E Alexander, W M Shea, P Y Wen, H A Fine, H M Kooy, P M Black.   

Abstract

PURPOSE: Between May 1988 and May 1991, 41 patients with malignant gliomas were enrolled onto a prospective study designed to evaluate the role of radiosurgery as a component of initial management. PATIENTS AND METHODS: Thirty-seven patients underwent radiosurgery according to the protocol and were assessable for survival and complications of treatment. Diagnoses included glioblastoma multiforme (GBM) in 23 (62%) cases and anaplastic astrocytoma in 14 (38%) cases. In 20 (54%) cases, surgical resection was attempted initially, whereas 17 (46%) patients underwent biopsy only. Patients in the study group received external-beam radiotherapy that consisted of 5,940 cGy given in 33 fractions to partial brain fields that encompassed the primary tumor with a 3 to 4 cm margin. Radiosurgery, used as a technique for boosting the dose to any residual contrast-enhancing mass lesion, was given 2 to 4 weeks after the completion of conventional radiotherapy. Minimum radiosurgical doses ranged from 1,000 to 2,000 cGy (median, 1,200 cGy), whereas maximum doses ranged from 1,250 to 2,500 cGy (median, 1,500 cGy). The median tumor volume at the time of radiosurgery was 4.8 cm3 (range, 1.2 to 72 cm3). Adjuvant chemotherapy was not given.
RESULTS: After a median follow-up of 19 months, only nine of 37 (24%) patients have died. Six patients (all glioblastoma multiforme) died of recurrent tumor, whereas death was attributable to complications of treatment in two cases and intercurrent disease in one case. Four patients with recurrent tumor failed at the margins of the radiosurgical treatment volume, whereas two patients progressed locally. One patient is alive with local and marginal failure. Seven (19%) patients underwent reoperation at a median time of 5 months (range, 1 to 14 months) after radiosurgery.
CONCLUSION: We conclude that radiosurgery is a useful adjunct to other modalities in the initial management of patients with small, radiographically well-defined malignant gliomas.

Entities:  

Mesh:

Year:  1992        PMID: 1325539     DOI: 10.1200/JCO.1992.10.9.1379

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  43 in total

Review 1.  Radiation medicine innovations for the new millenium.

Authors:  Dwight E Heron; Karen D Godette; Ray A Wynn; V Elayne Arterbery; Oscar A Streeter; Mack Roach; Joseph R Simpson; Melissa Blough; Charles R Thomas
Journal:  J Natl Med Assoc       Date:  2003-01       Impact factor: 1.798

2.  The use of a simple Likert scale to measure quality of life in brain tumor patients.

Authors:  M P Rogers; J Orav; P M Black
Journal:  J Neurooncol       Date:  2001-11       Impact factor: 4.130

Review 3.  Reevaluating stereotactic radiosurgery for glioblastoma: new potential for targeted dose-escalation.

Authors:  Ted K Yanagihara; Heva J Saadatmand; Tony J C Wang
Journal:  J Neurooncol       Date:  2016-09-08       Impact factor: 4.130

4.  [Value of radiosurgery in first-line therapy of glioblastoma multiforme. The Heidelberg experience and review of the literature].

Authors:  M van Kampen; R Engenhart-Cabillic; J Debus; M Fuss; B Rhein; M Wannenmacher
Journal:  Strahlenther Onkol       Date:  1998-04       Impact factor: 3.621

5.  Contributions of cell kill and posttreatment tumor growth rates to the repopulation of intracerebral 9L tumors after chemotherapy: an MRI study.

Authors:  B D Ross; Y J Zhao; E R Neal; L D Stegman; M Ercolani; O Ben-Yoseph; T L Chenevert
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

Review 6.  New Hypofractionation Radiation Strategies for Glioblastoma.

Authors:  Melissa Azoulay; Jennifer Shah; Erqi Pollom; Scott G Soltys
Journal:  Curr Oncol Rep       Date:  2017-09       Impact factor: 5.075

7.  Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma.

Authors:  Marc C Chamberlain; Sandra Johnston
Journal:  J Neurooncol       Date:  2008-10-25       Impact factor: 4.130

Review 8.  The basis for current treatment recommendations for malignant gliomas.

Authors:  H A Fine
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

9.  Pilot study of estramustine added to radiosurgery and radiotherapy for treatment of high grade glioma.

Authors:  Howard Landy; Arnold Markoe; Priscilla Potter; Garrett Lasalle; Angela Marini; Niramol Savaraj; Isildinha Reis; Deborah Heros; Medhi Wangpaichitr; Lynn Feun
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

10.  Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme--a dosimetric comparison.

Authors:  Marc D Piroth; Michael Pinkawa; Richard Holy; Gabriele Stoffels; Cengiz Demirel; Charbel Attieh; Hans J Kaiser; Karl J Langen; Michael J Eble
Journal:  Radiat Oncol       Date:  2009-11-23       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.